ImmunoGuide®

Instructions for Use

Omalizumab ELISA
(mAb-based)

Enzyme immunoassay for the specific and quantitative determination of free Omalizumab in serum and plasma

REF: IG-AB111

$\sum$ 12X8   📖   ☀   🌡 2-8°C

CE   IVD

Contents   **Page**

1. INTENDED USE

Enzyme immunoassay for the specific and quantitative determination of free Omalizumab in serum and plasma.

2. SUMMARY AND EXPLANATION

Omalizumab (trade name Xolair®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody and it binds to human immunoglobulin E (IgE). The molecular weight of omalizumab is 149 kilodlatons and is produced by Chinese hamster ovary cell suspension culture. Omalizumab inhibits the binding of IgE to IgE receptor (FcεRI) on the surface of mast cells and basophils. Therefore, the Omalizumab is expected to limit the degree of release of mediators of the allergic response from the FcεRI bearing cells.

This *ImmunoGuide* Omalizumab ELISA (mAb-based) is developed for the specific measurement of Omalizumab in serum, plasma and other biological fluids by the advantage of using a site-directed IG-Ulkr4H1 mouse monoclonal antibody (mAb) specific for Omalizumab only. Binding of Omalizumab to the solid phase, pre-coated with IG-Ulkr4H1, is inhibited by human IgE in a concentration dependent manner. Therefore, the ImmunoGuide Omalizumab ELISA (mAb-based) measures the free form of Omalizumab only. The choice of specifically measuring the free form allows investigators to analyze the concentration-effect relationship. The *ImmunoGuide* Omalizumab ELISA (mAb-based) kit can be efficiently used for measuring free Omalizumab levels in serum and plasma.

3. PRINCIPLE OF THE TEST

This ELISA is based on Omalizumab-specific monoclonal antibody (catcher Ab, *ImmunoGuide* clone Ulkr4H1). Standards and diluted samples are incubated in the microtiter plate coated with IG-Ulkr4H1 mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Omalizumab. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of a chromogen-substrate. The color developed is proportional to the amount of Omalizumab in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Omalizumab to the solid phase, precoated with IG-Ulkr4H1, is inhibited by human IgE in a concentration dependent manner. Therefore, the ImmunoGuide Omalizumab ELISA (mAb-based) measures the free form of Omalizumab only.

4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.

2. In case of severe damage of the kit package, please contact *AybayTech* or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.

3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.

4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.

5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.

6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.

7. Avoid contact with Stop solution. It may cause skin irritations and burns.

8. If any component of this kit contains human serum or plasma it is indicated and if so, it have been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.

9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.

6. SPECIMEN COLLECTION, HANDLING AND STORAGE
Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	≤-20°C (Aliquots)	Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles
Stability:	3 d	6 mon	

7. CONTENTS OF THE KIT

QUANTITY	COMPONENT
1 x 12 x 8	**Microtiter Plate** Break apart strips coated with anti-Omalizumab monoclonal antibody.
5 x 0.5 mL	**Omalizumab Standards A-E, Concentrate (10X)** 1000; 300; 100; 30; and 0 ng/mL Used for construction of the standard curve. Contains Omalizumab, proteins, preservative and stabilizer.
1 x 12 mL	**Assay Buffer** Blue colored. Ready to use. Contains proteins and preservative.
1 x 60 mL	**Dilution Buffer,** Concentrate (5X) Contains orange dye, proteins and preservative.
1 x 12 mL	**Enzyme Conjugate** Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin® and stabilizers.
1 x 12 mL	**TMB Substrate Solution** Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
1 x 12 mL	**Stop Solution** Ready to use. 1 N Hydrochloric acid (HCl).
1 x 50 mL	**Wash Buffer**, Concentrate (20x) Contains buffer, Tween® 20 and Kathon™.
2 x 1	**Adhesive Seal** For sealing microtiter plate during incubation.

8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.

2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.

3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.

4. Use a pipetting scheme to verify an appropriate plate layout.

5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.

6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.

7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components*

| Dilute/ dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer	up to 200 mL	Distilled Water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	4 w
10 mL	Dilution Buffer	up to 50 mL	Distilled Water	1:5		2-8 °C	4 w

* Prepare Wash and Dilution Buffers before starting the assay procedure.

10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final dilutions for standards and samples. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 10 µL of standard or sample added to 90 µL of 1X dilution buffer, giving the total volume of 100 µL and a dilution of 1:10.
2. 10 µL of 1:10 diluted sample added to 990 µL of 1X dilution buffer, giving the total volume of 1000 µL and a dilution of 1:1000. This 2nd dilution should NOT be done with the standards.
3. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

Standard/Sample Dilution

11. TEST PROCEDURE
11.1. GENERAL REMARKS

11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
11.1.2. All Standards should be run with each series of unknown samples.
11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.
11.1.4. All steps of the test should be completed without interruption.
11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.

11.2. ASSAY PROCEDURE

1.	Pipette **100μl** of **Assay Buffer** into each of the wells to be used.
2.	Pipette **75 μL** of each **1:10 Diluted Standard, and 1:1000 Diluted Samples** into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided. Wells A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Samples (Serum/Plasma)
3.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. **Incubate the plate on a bench top for 60 min** at **room temperature (RT, 20-25°C)**.
4.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate **5 X 350 μL** of **Diluted Wash Buffer** per well. Remove excess solution by tapping the inverted plate on a paper towel.
5.	Pipette **100 μL** of **Enzyme Conjugate** ((HRP-anti human IgG mAb) into each well.
6.	Cover plate with adhesive seal. Shake plate carefully by tapping several times. **Incubate the plate on a bench top for 30 min** at RT.
7.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate **5 X 350 μL** of **Diluted Wash Buffer** per well. Remove excess solution by tapping the inverted plate on a paper towel.
8.	Pipette **100 μL** of Ready-to-Use **TMB** Substrate Solution into each well.
9.	**Incubate 10 min** at RT. Avoid exposure to direct sunlight.
10.	Stop the substrate reaction by adding **100 μL** of **Stop Solution** into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
11.	Measure optical density (OD) with a photometer at **450 nm** (Reference at OD620 nm is optional) within **15 min** after pipetting the Stop Solution.

11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

11. 4. CALCULATION OF RESULTS

A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at http://www.papersnake.com/logarithmic/semilogarithmic/.

The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor (usually 1000). If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

Typical Calibration Curve
(All steps were performed at 23°C. Just an example. Do not use it for calculation!)

1:10 Diluted Standard	A	B	C	D	E
Concentration (ng/mL)	100	30	10	3	0
Mean OD450/620 nm	2.904	1.177	0.406	0.130	0.016

Fig. A

Fig. B

12. ASSAY CHARACTERISTICS

12.1. SPECIFICITY
There is no cross reaction with any other proteins present in native human serum. A screening test was performed with different native human sera. All produced OD450/620 nm values less than the mean OD of standard D (3 ng/mL). In addition, human IgE antibody was also separately tested at concentrations up to 100 µg/mL and cross reaction was NOT observed. No cross reaction was observed with sera spiked with the other therapeutic antibodies including Infliximab, Adalimumab, Etanercept, Rituximab, Trastuzumab, Tocilizumab and Bevacizumab at concentrations up to 2 mg/mL. All produced mean OD450/620 nm values less than the mean OD of standard D.

12.2. SENSITIVITY
The lowest detectable level that can be clearly distinguished from the zero standard is 1 ng/mL (zero standard +2SD read from the curve) under the above-described conditions. Analytical sensitivity is 1 ng/mL, and corresponding to the detection limit (limit of quantification) of 1 µg/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:1000 before starting the assay.

12.3. PRECISION OF THE KIT
Intra-assay CV: <10%.
Inter-assay CV: <10%.

12.4. RECOVERY
Recovery rate was found to be >95% with native human serum and plasma samples when spiked with exogenous Omalizumab.

13. AUTOMATION
The *ImmunoGuide* Omalizumab ELISA (mAb-based) is suitable also for being used by an automated ELISA processor.

14.REFERENCES

1. Rasmus K. Jensen, Melanie Plum, Luna Tjerrild, et al., Structure of the omalizumab Fab. Acta Cryst. (2015). F71, 419–426.

2. Lowe PJ, Georgiou P, Canvin J. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. Regul Toxicol Pharmacol. 2015 Feb;71(1):68-77.

3. Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, Rosén K, Omachi TA, Khalil S, Zazzali JL. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016 Feb;137(2):474-81.

4. Roth M, Zhao F, Zhong J, Lardinois D, Tamm M. Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab. PLoS One. 2015 Sep 2;10(9):e0136549. doi: 10.1371.

5. Stelmach I, Majak P, Jerzyńska J, Bojo M, Cichalewski Ł, Smejda K. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland. Arch Med Sci. 2015;11(4):901-4.

6. Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, Cao C, Ying S, Chen Z, Li W, Wu B, Shen H. Corrigendum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015 Aug 14;5:9548. doi: 10.1038/srep09548.

7. Beam KT, Coop CA. Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis. Allergy Rhinol (Providence). 2015; 6(2): 143-5.

8. Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and Physical Basis for Anti-IgE Therapy. Sci Rep. 2015 Jun 26;5:11581. doi: 10.1038/srep11581.

9. Yalcin AD. Advances in anti-IgE therapy. Biomed Res Int. 2015;2015:317465. doi: 10.1155/2015/317465.

10. Cooke A, Bulkhi A, Casale TB. Role of biologics in intractable urticaria. Biologics. 2015;9:25-33.

11. D'Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, Molino A, Vatrella A, D'Amato M. Treating severe allergic asthma with anti-IgE

monoclonal antibody (omalizumab): a review. Multidiscip Respir Med. 2014;9(1):23. doi: 10.1186/2049-6958-923. eCollection 2014. Review

12. Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulm Pharmacol Ther. 2014;28(2):149-53.

13. Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O'Connor GT, Pongracic JA, Ross K, Gill MA, Kattan M, Morgan WJ, Teach SJ, Gergen PJ, Liu AH, Szefler SJ. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163-71.

14. Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther. 2014;8:197-207.

15. Baker DL, Peng K, et al., Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin. 2014;30(5):913-22.

16. Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2014;30(1):59-66.

17. Mortensen DL, Prabhu S, Stefanich EG, Kadkhodayan-Fischer S, Gelzleichter TR, Baker D, Jiang J, Wallace K, Iyer S, Fielder PJ, Putnam WS. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs. 2012;4(6):724-31.

18. Song CH, Stern S, Giruparajah M, Berlin N, Sussman GL. Long-term efficacy of fixeddose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013;110(2):113-7.

19. Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106(11):1494-500.

20. Matsuno O, Komori C, Hang Y, Matsumoto T, Minamoto S. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy. J Asthma. 2012;49(8):839-42.